<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-14T03:26:59Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:10256/24663" metadataPrefix="oai_dc">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:10256/24663</identifier><datestamp>2025-05-01T19:00:24Z</datestamp><setSpec>com_2072_452955</setSpec><setSpec>com_2072_2054</setSpec><setSpec>col_2072_452960</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
   <dc:title>Endothelial dysfunction and cardiovascular risk in post-COVID-19 patients after 6- and 12-months SARS-CoV-2 infection</dc:title>
   <dc:creator>Poyatos Dorado, Paula</dc:creator>
   <dc:creator>Luque, Neus</dc:creator>
   <dc:creator>Sabater Talaverano, Gladis</dc:creator>
   <dc:creator>Eizaguirre, Saioa</dc:creator>
   <dc:creator>Bonnin Vilaplana, Marc</dc:creator>
   <dc:creator>Orriols Martínez, Ramon</dc:creator>
   <dc:creator>Tura-Ceide, Olga</dc:creator>
   <dc:subject>Sistema cardiovascular -- Malalties</dc:subject>
   <dc:subject>Cardiovascular system -- Diseases</dc:subject>
   <dc:subject>COVID-19 (Malaltia)</dc:subject>
   <dc:subject>COVID-19 (Disease)</dc:subject>
   <dc:subject>Endoteli</dc:subject>
   <dc:subject>Endothelium</dc:subject>
   <dc:description>SARS-CoV-2 infection causes severe endothelial damage, an essential step for cardiovascular complications. Endothelial-colony forming cells (ECFCs) act as a biomarker of vascular damage but their role in SARS-CoV-2 remain unclear. The aim of this study was to assess whether the number of ECFCs and angiogenic biomarkers remained altered after 6 and 12-months post-infection and whether this imbalance correlated with the presence of long-COVID syndrome and other biological parameters measured.&#xd;
&#xd;
Methods&#xd;
Seventy-two patients were recruited at different time-points after overcoming COVID-19 and thirty-one healthy controls. All subjects were matched for age, gender, BMI, and comorbidities. ECFCs were obtained from peripheral blood and cultured with specific conditions.&#xd;
&#xd;
Results&#xd;
The results confirm the presence of a long-term sequela in post-COVID-19 patients, with an abnormal increase in ECFC production compared to controls (82.8% vs. 48.4%, P &lt; 0.01) that is maintained up to 6-months (87.0% vs. 48.4%, P &lt; 0.01) and 12-months post-infection (85.0% vs. 48.4%, P &lt; 0.01). Interestingly, post-COVID-19 patients showed a significant downregulation of angiogenesis-related proteins compared to controls indicating a clear endothelial injury. Troponin, NT-proBNP and ferritin levels, markers of cardiovascular risk and inflammation, remained elevated up to 12-months post-infection. Patients with lower numbers of ECFC exhibited higher levels of inflammatory markers, such as ferritin, suggesting that ECFCs may play a protective role. Additionally, long-COVID syndrome was associated with higher ferritin levels and with female gender.&#xd;
&#xd;
Conclusions&#xd;
These findings highlight the presence of vascular sequela that last up to 6- and 12-months post-infection and point out the need for preventive measures and patient follow-up</dc:description>
   <dc:description>Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature</dc:description>
   <dc:date>2024-08</dc:date>
   <dc:type>info:eu-repo/semantics/article</dc:type>
   <dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
   <dc:type>peer-reviewed</dc:type>
   <dc:identifier>http://hdl.handle.net/10256/24663</dc:identifier>
   <dc:identifier>38324145</dc:identifier>
   <dc:identifier>PMC11289012</dc:identifier>
   <dc:language>eng</dc:language>
   <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1007/s15010-024-02173-5</dc:relation>
   <dc:relation>info:eu-repo/semantics/altIdentifier/issn/0300-8126</dc:relation>
   <dc:relation>info:eu-repo/semantics/altIdentifier/eissn/1439-0973</dc:relation>
   <dc:rights>Attribution 4.0 International</dc:rights>
   <dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
   <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
   <dc:format>application/pdf</dc:format>
   <dc:publisher>Springer</dc:publisher>
   <dc:source>Infection, 2024, vol. 52, p. 1269-1285</dc:source>
   <dc:source>Articles publicats (D-CM)</dc:source>
</oai_dc:dc></metadata></record></GetRecord></OAI-PMH>